Supernus to Participate in Annual Piper Sandler Healthcare Conference
ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate in a fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29 – December 2, 2021. The Company will also host investor meetings on Wednesday, December 1, 2021.
The pre-recorded fireside chat can be accessed beginning at 10:00 a.m. ET on November 22, 2021 by visiting Events & Presentations in the Investors section on the Company’s website at www.supernus.com. An archived replay of this fireside chat will be available for 60 days on the Company’s website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
